Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • DrD2009
    Member
    • Oct 2009
    • 88

    Bowtie and Cufflinks

    Hello,

    I have aligned Solexa sequencing data using Bowtie and plan on creating expression profiles using Cufflinks by looking at RPKM values.

    There is one thing I am curious about. Is there a way to compare your alignments to annotated regions, so you can give the reads a name along with an RPKM value? I'm assuming Cufflinks simply gives you a read and it's RPKM, what I would like is to be able to see X gene, X miRNA, X puesdogene has an RPKM value of Y.

    Is there a way to make this possible? Any suggestions would be great.


    Thanks,
    Brandon
  • mgogol
    Senior Member
    • Mar 2008
    • 197

    #2
    Cufflinks will give you a gene/transcript and its RPKM (if you feed it a gff file). If you don't, it will give you a "made up" gene/transcript and its RPKM.

    RPKM is always in terms of a larger genomic entity, not a single read. Reads per kilobase per million.

    Hi, fellow Kansas Citian!

    Comment

    • DrD2009
      Member
      • Oct 2009
      • 88

      #3
      mgogol, thank you for the reply.

      Do you work in bioinformatics here in the Kansas City area? I work at UMKC.

      Comment

      • mgogol
        Senior Member
        • Mar 2008
        • 197

        #4
        Yep, I'm at Stowers.

        Comment

        • RockChalkJayhawk
          Senior Member
          • Mar 2009
          • 192

          #5
          I'm at KU Med... Looks like KC is representing well.

          Comment

          • mgogol
            Senior Member
            • Mar 2008
            • 197

            #6
            I've seen your name around the forum... I went to KU, so it jumped out at me.

            Comment

            • RockChalkJayhawk
              Senior Member
              • Mar 2009
              • 192

              #7
              We should all get together sometime for lunch. It would be nice to talk face to face with others that actually understand what you are doing.

              Comment

              • mgogol
                Senior Member
                • Mar 2008
                • 197

                #8
                I emailed you...

                Comment

                • DrD2009
                  Member
                  • Oct 2009
                  • 88

                  #9
                  Kansas City seems to be well represented here.

                  Comment

                  Latest Articles

                  Collapse

                  • SEQadmin2
                    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                    by SEQadmin2


                    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                    The systematic characterization of the human proteome has
                    ...
                    07-20-2026, 11:48 AM
                  • SEQadmin2
                    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                    by SEQadmin2



                    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                    ...
                    07-09-2026, 11:10 AM
                  • SEQadmin2
                    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                    by SEQadmin2



                    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                    07-08-2026, 05:17 AM

                  ad_right_rmr

                  Collapse

                  News

                  Collapse

                  Topics Statistics Last Post
                  Started by SEQadmin2, 07-24-2026, 12:17 PM
                  0 responses
                  25 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-23-2026, 11:41 AM
                  0 responses
                  20 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-20-2026, 11:10 AM
                  0 responses
                  27 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-13-2026, 10:26 AM
                  0 responses
                  38 views
                  0 reactions
                  Last Post SEQadmin2  
                  Working...